Patheon expands stability testing capabilities

Company invests US$3m in equipment and talent in its centralised stability testing lab

Patheon is investing more than US$3m to expand stability testing capabilities at its Greenville site in North Carolina, US. The expansion includes the addition of advanced automated systems and the assembly of a highly experienced scientific team to enhance its centralised stability lab offerings.

Since 2011, more than 1,000 stability studies with 110 different products have been initiated at Patheon’s stability lab in Greenville. With this expansion, the facility now offers more than 30,000ft3 of state-of-the-art stability storage, and the capabilities to support the largest, most complex projects on small molecule APIs, large molecule biologics and drug substances, solid oral dose drugs, sterile liquid or lyophilised drugs, controlled substances and highly potent compounds.

‘Our complete suite of advanced analytical tools dedicated to stability testing delivers accelerated results for customers’ late-stage development and commercial projects, providing high-quality data in 30 days or fewer,’ said Dr Bill Weiser, Executive Director and Global Head of Analytical Sciences.

‘An additional benefit is that the stability lab’s high-tech chromatography system will be fully integrated with the data reporting system, which allows customers to access their data any time, anywhere, allowing for quicker access to submission-ready reports,’ he added.

Patheon says the investment in its Greenville facility demonstrates its commitment to continued growth and customer needs. Companies facing costly upgrades to their in-house stability capabilities will benefit greatly from the use of Patheon’s efficient and cost-effective centralised stability services.

Companies